Clinical Trial Update: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating REGN2810 (cemiplimab) followed by chemoimmunotherapy for newly metastatic hormone-sensitive prostate cancer, with the study currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: Mark Stein | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: ACTIVE_NOT_RECRUITING